NASDAQ$LGVN

Longeveron Inc-A · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Reported financial results for the third quarter ended September 30, 2021.

Longeveron Inc. reported revenue of $0.2 million and a net loss of $4.9 million for the third quarter of 2021. The company's cash and short term investments amounted to $19.0 million. They believe that their existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

  • Revenue for the third quarter 2021 was $0.2 million, compared to $1.8 million in the same period in 2020.
  • Research and development expenses in the third quarter of 2021 were $2.0 million, compared to $0.6 million for the same period in 2020.
  • General and administrative expenses in the third quarter of 2021 were $3.0 million, compared to $0.7 million for the same period in 2020.
  • Net loss was $4.9 million in the third quarter 2021, compared to $0.9 million for the same period in 2020.

Headline financials

Total Revenue

$232K

Previous: $1.87M-87.6%
EPS (adj)

-$2.50

Previous: -$0.59-326.9%
Capital Expenditures

-$18K

No prior period
Free Cash Flow

-$13M

No prior period
Net Income

-$13M

Previous: -$938K-1283.4%
Operating Income

-$4.91M

Previous: -$958K-412.0%
Gross Profit

$164K

Previous: $373K-56.0%
Cash & Equivalents

$9.74M

No prior period
Total Assets

$27.2M

No prior period
Stock-Based Comp

$35K

No prior period

Revenue & EPS history

Longeveron · Revenue · Quarterly

$232K

Q3 2021-87.6%vs Q3 2020
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Revenue by segment

Longeveron · $150K total across 1 segment · Q4 2023

  • Clinical Trial Revenue
    $150K

Forward guidance

Based on the Company’s current operating plan and financial resources, we believe that our existing cash on hand will be sufficient to cover expenses and capital requirements through at least the fourth quarter of 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-5.1%

Avg return

Earnings day

-5.7%

Avg return

5 days after

+22.2%

Avg return

30 days after

35%

7 / 20 earnings

Positive

+10.0%

Q1 2022

Best reaction

-35.7%

Q2 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.7%-11.0%+4.3%
Q4 2025-4.7%-0.7%+6.1%
Q3 2025-4.3%-7.3%-23.1%
Q1 2025-10.1%-9.4%-17.4%
Q4 2024-9.2%-5.3%+2.0%
Q3 2024-2.3%-8.8%-14.3%
Q2 2024-7.5%-11.3%-21.8%
Q1 2024+3.1%-1.5%+106.9%
Q4 2023+0.7%+0.0%-39.8%
Q3 2023-6.7%-0.5%+17.6%
Q2 2023-6.5%-12.0%-25.8%
Q1 2023-6.1%-11.9%-0.9%
Q4 2022-15.5%-17.5%-25.0%
Q3 2022+5.1%+2.6%-14.1%
Q2 2022+3.9%+1.3%-14.5%
Q1 2022+10.0%+16.2%-0.7%
Q4 2021-14.4%-7.1%+37.8%
Q3 2021-4.9%-15.6%+461.6%
Q2 2021-35.7%-32.9%-31.1%
Q1 2021+1.7%+17.9%+35.8%
Q3 2020
Q2 2020
Q1 2020
Q4 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro